518 related articles for article (PubMed ID: 12201500)
1. A phase II study of Irofulven (MGI 114) in patients with stage IV melanoma.
Pierson AS; Gibbs P; Richards J; Russ P; Eckhardt SG; Gonzalez R
Invest New Drugs; 2002 Aug; 20(3):357-62. PubMed ID: 12201500
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
Eckhardt SG; Baker SD; Britten CD; Hidalgo M; Siu L; Hammond LA; Villalona-Calero MA; Felton S; Drengler R; Kuhn JG; Clark GM; Smith SL; MacDonald JR; Smith C; Moczygemba J; Weitman S; Von Hoff DD; Rowinsky EK
J Clin Oncol; 2000 Dec; 18(24):4086-97. PubMed ID: 11118470
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with advanced non-small cell cancer previously treated with chemotherapy.
Dowell JE; Johnson DH; Rogers JS; Shyr Y; McCullough N; Krozely P; DeVore RF
Invest New Drugs; 2001; 19(1):85-8. PubMed ID: 11291837
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer.
Seiden MV; Gordon AN; Bodurka DC; Matulonis UA; Penson RT; Reed E; Alberts DS; Weems G; Cullen M; McGuire WP
Gynecol Oncol; 2006 Apr; 101(1):55-61. PubMed ID: 16260029
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical and pharmacokinetic trial of irofulven.
Thomas JP; Arzoomanian R; Alberti D; Feierabend C; Binger K; Tutsch KD; Steele T; Marnocha R; Smith C; Smith S; MacDonald J; Wilding G; Bailey H
Cancer Chemother Pharmacol; 2001 Dec; 48(6):467-72. PubMed ID: 11800027
[TBL] [Abstract][Full Text] [Related]
6. Irofulven, a novel inhibitor of DNA synthesis, in metastatic renal cell cancer.
Amato RJ; Perez C; Pagliaro L
Invest New Drugs; 2002 Nov; 20(4):413-7. PubMed ID: 12448659
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia.
Giles F; Cortes J; Garcia-Manero G; Kornblau S; Estey E; Kwari M; Murgo A; Kantarjian H
Invest New Drugs; 2001; 19(1):13-20. PubMed ID: 11291829
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors.
Bomgaars LR; Megason GC; Pullen J; Langevin AM; Dale Weitman S; Hershon L; Kuhn JG; Bernstein M; Blaney SM
Pediatr Blood Cancer; 2006 Aug; 47(2):163-8. PubMed ID: 16317728
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group.
Schilder RJ; Blessing JA; Pearl ML; Rose PG
Invest New Drugs; 2004 Aug; 22(3):343-9. PubMed ID: 15122083
[TBL] [Abstract][Full Text] [Related]
10. A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors.
Alexandre J; Kahatt C; Bertheault-Cvitkovic F; Faivre S; Shibata S; Hilgers W; Goldwasser F; Lokiec F; Raymond E; Weems G; Shah A; MacDonald JR; Cvitkovic E
Invest New Drugs; 2007 Oct; 25(5):453-62. PubMed ID: 17628744
[TBL] [Abstract][Full Text] [Related]
11. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
Leggas M; Stewart CF; Woo MH; Fouladi M; Cheshire PJ; Peterson JK; Friedman HS; Billups C; Houghton PJ
Clin Cancer Res; 2002 Sep; 8(9):3000-7. PubMed ID: 12231547
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma.
Berg WJ; Schwartz L; Yu R; Mazumdar M; Motzer RJ
Invest New Drugs; 2001; 19(4):317-20. PubMed ID: 11561691
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix.
Kudelka AP; Levy T; Verschraegen CF; Edwards CL; Piamsomboon S; Termrungruanglert W; Freedman RS; Kaplan AL; Kieback DG; Meyers CA; Jaeckle KA; Loyer E; Steger M; Mante R; Mavligit G; Killian A; Tang RA; Gutterman JU; Kavanagh JJ
Clin Cancer Res; 1997 Sep; 3(9):1501-5. PubMed ID: 9815836
[TBL] [Abstract][Full Text] [Related]
14. Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trial.
Senzer N; Arsenau J; Richards D; Berman B; MacDonald JR; Smith S
Am J Clin Oncol; 2005 Feb; 28(1):36-42. PubMed ID: 15685033
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer.
Sherman CA; Herndon JE; Watson DM; Green MR;
Lung Cancer; 2004 Sep; 45(3):387-92. PubMed ID: 15301880
[TBL] [Abstract][Full Text] [Related]
16. Characterization and multiparameter analysis of visual adverse events in irofulven single-agent phase I and II trials.
Raymond E; Kahatt C; Rigolet MH; Sutherland W; Lokiec F; Alexandre J; Tombal B; Elman M; Lee MS; MacDonald JR; Cullen M; Misset JL; Cvitkovic E
Clin Cancer Res; 2004 Nov; 10(22):7566-74. PubMed ID: 15569987
[TBL] [Abstract][Full Text] [Related]
17. Piperazinedione in patients with advanced malignant melanoma: a Southwest Oncology Group study.
Al-Sarraf M; Thigpen T; Groppe CW; Haut A; Padilla F
Cancer Treat Rep; 1978 Jul; 62(7):1101-3. PubMed ID: 356973
[TBL] [Abstract][Full Text] [Related]
18. Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG).
Yeo W; Boyer M; Chung HC; Ong SY; Lim R; Zee B; Ma B; Lam KC; Mo FK; Ng EK; Ho R; Clarke S; Roh JK; Beale P; Rha SY; Jeung HC; Soo R; Goh BC; Chan AT;
Cancer Chemother Pharmacol; 2007 Feb; 59(3):295-300. PubMed ID: 16783579
[TBL] [Abstract][Full Text] [Related]
19. Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C.
Kelner MJ; McMorris TC; Rojas RJ; Trani NA; Estes L
Cancer Chemother Pharmacol; 2002 May; 49(5):412-8. PubMed ID: 11976836
[TBL] [Abstract][Full Text] [Related]
20. Bleomycin, vinorelbine and trofosfamide in relapsed stage IV cutaneous malignant melanoma patients.
Atzpodien J; Morawek L; Fluck M; Reitz M
Cancer Chemother Pharmacol; 2009 Oct; 64(5):901-5. PubMed ID: 19229537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
